XEN 801

Drug Profile

XEN 801

Alternative Names: XEN801

Latest Information Update: 12 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Xenon Pharmaceuticals
  • Class Antiacnes; Small molecules
  • Mechanism of Action Stearoyl CoA desaturase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acne vulgaris
  • Preclinical Skin disorders

Most Recent Events

  • 01 Mar 2017 Xenon Pharmaceuticals completes a phase I/II trial for Acne Vulgaris (In volunteers) in Canada (Topical) (NCT02656043)
  • 04 Nov 2016 Xenon Pharmaceuticals completes enrolment in its phase I/II trial for Acne Vulgaris (In volunteers) in Canada (Topical) (NCT02656043)
  • 10 Feb 2016 Phase-II clinical trials in Acne vulgaris in Canada (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top